Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets
April 1, 2026 11:42 AM
ACCESS Newswire
CHICAGO, IL / ACCESS Newswire / April 1, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that C-Scrub Wash 4%, manufactured by its wholly owned subsidiary Cana Laboratories S.A., has successfully completed testing under EN 12791:2016+A1:2017, the European standard for surgical hand disinfection.
The independent study, conducted by Quality Assurance & Control Systems Ltd. (QACS), a Greece-based testing and certification laboratory specializing in microbiological and disinfectant efficacy studies, confirmed that C-Scrub Wash 4% demonstrated effective antimicrobial activity for surgical hand disinfection in accordance with EN 12791 requirements. The product is formulated with 4% Chlorhexidine Digluconate and is designed for use in healthcare and clinical environments requiring high standards of hygiene and infection prevention.
EN 12791 is a widely recognized European benchmark for surgical hand antisepsis products and supports entry into hospital, surgical, and professional healthcare channels. The Company believes that successful completion of this study strengthens the clinical positioning of C-Scrub Wash 4% and opens additional commercial opportunities across international healthcare markets.
This milestone comes as C-Scrub continues gaining traction across several key markets, including the United Kingdom, where Cosmos Health has recently announced expanding commercial availability and growing market presence. The Company believes the EN 12791 study completion further supports its strategy to expand the C-Scrub portfolio across both retail and institutional healthcare channels.
The Company believes that this achievement further strengthens Cosmos Health's infection control portfolio, enhances the commercial positioning of the C-Scrub brand, and supports continued international growth.
Greg Siokas, CEO of Cosmos Health, stated: "The successful completion of the EN 12791 study for C-Scrub Wash 4% represents an important milestone for Cosmos Health. As demand for infection control solutions continues to grow across key markets, this achievement enhances the clinical credibility of our C-Scrub portfolio and supports expansion into hospital, surgical, and institutional healthcare markets globally. By achieving technical parity with established industry benchmarks, we reduce barriers to entry, strengthen our competitive positioning, and support projected sales growth across key healthcare markets."
C-Scrub Wash 4% is a powerful antiseptic skin cleanser formulated with 4% Chlorhexidine Digluconate, designed to deliver broad antimicrobial protection. The product offers reliable disinfectant properties to help reduce bacteria and support infection prevention, making it suitable for healthcare professionals and clinical environments requiring high standards of hygiene.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company's business, operations, and the economy in general; and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS NewswireOriginal: Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets
Market Data 
Markets 
